148 related articles for article (PubMed ID: 22705145)
1. Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1).
Strobel J; Mieth M; Endress B; Auge D; König J; Fromm MF; Maas R
J Mol Cell Cardiol; 2012 Sep; 53(3):392-400. PubMed ID: 22705145
[TBL] [Abstract][Full Text] [Related]
2. The prognostic biomarker L-homoarginine is a substrate of the cationic amino acid transporters CAT1, CAT2A and CAT2B.
Chafai A; Fromm MF; König J; Maas R
Sci Rep; 2017 Jul; 7(1):4767. PubMed ID: 28684763
[TBL] [Abstract][Full Text] [Related]
3. Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).
Strobel J; Müller F; Zolk O; Endreß B; König J; Fromm MF; Maas R
Amino Acids; 2013 Oct; 45(4):989-1002. PubMed ID: 23864433
[TBL] [Abstract][Full Text] [Related]
4. Screening of commonly prescribed drugs for effects on the CAT1-mediated transport of L-arginine and arginine derivatives.
Banjarnahor S; König J; Maas R
Amino Acids; 2022 Jul; 54(7):1101-1108. PubMed ID: 35377022
[TBL] [Abstract][Full Text] [Related]
5. The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine.
Taghikhani E; Maas R; Fromm MF; König J
PLoS One; 2019; 14(3):e0213747. PubMed ID: 30865704
[TBL] [Abstract][Full Text] [Related]
6. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
7. The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood-brain barrier in vitro.
Watson CP; Pazarentzos E; Fidanboylu M; Padilla B; Brown R; Thomas SA
Brain Res; 2016 Oct; 1648(Pt A):232-242. PubMed ID: 27431938
[TBL] [Abstract][Full Text] [Related]
8. Real-time functional characterization of cationic amino acid transporters using a new FRET sensor.
Vanoaica L; Behera A; Camargo SM; Forster IC; Verrey F
Pflugers Arch; 2016 Apr; 468(4):563-72. PubMed ID: 26555760
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells.
Davids M; Teerlink T
Metabolism; 2013 Oct; 62(10):1455-61. PubMed ID: 23890667
[TBL] [Abstract][Full Text] [Related]
10. Transport of L-Arginine Related Cardiovascular Risk Markers.
Banjarnahor S; Rodionov RN; König J; Maas R
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33302555
[TBL] [Abstract][Full Text] [Related]
11. Impact of Cationic Amino Acid Transporter 1 on Blood-Retinal Barrier Transport of L-Ornithine.
Kubo Y; Obata A; Akanuma S; Hosoya K
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5925-32. PubMed ID: 26377079
[TBL] [Abstract][Full Text] [Related]
12. The biological effect of pharmacological treatment on dimethylaminohydrolases (DDAH-1) and cationic amino acid transporter-1 (CAT-1) expression in patients with acute congestive heart failure.
Speranza L; Franceschelli S; D'Orazio N; Gaeta R; Bucciarelli T; Felaco M; Grilli A; Riccioni G
Microvasc Res; 2011 Nov; 82(3):391-6. PubMed ID: 21722652
[TBL] [Abstract][Full Text] [Related]
13. Developmental changes of l-arginine transport at the blood-brain barrier in rats.
Tachikawa M; Hirose S; Akanuma SI; Matsuyama R; Hosoya KI
Microvasc Res; 2018 May; 117():16-21. PubMed ID: 29247719
[TBL] [Abstract][Full Text] [Related]
14. Cationic amino acid transporter 1-mediated L-arginine transport at the inner blood-retinal barrier.
Tomi M; Kitade N; Hirose S; Yokota N; Akanuma S; Tachikawa M; Hosoya K
J Neurochem; 2009 Nov; 111(3):716-25. PubMed ID: 19712052
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric and symmetric dimethylarginine are associated with coronary artery lesions in Kawasaki disease.
Huang YH; Tain YL; Lee CP; Kuo HC
J Pediatr; 2014 Aug; 165(2):295-9. PubMed ID: 24874168
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress.
Zhang WZ; Venardos K; Chin-Dusting J; Kaye DM
Hypertension; 2006 Aug; 48(2):278-85. PubMed ID: 16801489
[TBL] [Abstract][Full Text] [Related]
17. Quantification of L-arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma: a step improvement in precision by stable isotope dilution mass spectrometry.
Martens-Lobenhoffer J; Bode-Böger SM
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 904():140-3. PubMed ID: 22884474
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases.
Böger RH; Bode-Böger SM
Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410
[TBL] [Abstract][Full Text] [Related]
19. Changes of differentiation and proliferation in k562 cells with various levels of knockdown of cationic amino acid transporter 1.
Maeda T; Shima Y; Sugiura S; Aizawa S; Tamai I
Drug Metab Pharmacokinet; 2008; 23(3):181-7. PubMed ID: 18574322
[TBL] [Abstract][Full Text] [Related]
20. Health-associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with high-performance liquid chromatography.
Hov GG; Sagen E; Bigonah A; Asberg A
Scand J Clin Lab Invest; 2007; 67(8):868-76. PubMed ID: 17852822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
